Montelukast
Montelukast.JPG

CLINICAL USE

Prophylaxis of asthma

DOSE IN NORMAL RENAL FUNCTION

10 mg at night

PHARMACOKINETICS

  • Molecular weight                           :608.2 (as sodium salt)
  • %Protein binding                           :>99
  • %Excreted unchanged in urine     : <0.2
  • Volume of distribution (L/kg)       :8–11 litres
  • half-life – normal/ESRD (hrs)      :2.7–5.5

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : Dose as in normal renal function
  • 10 to 20     : Dose as in normal renal function
  • <10           : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :Not dialysed. Dose as in normal renal function
  • HD                     :Not dialysed. Dose as in normal renal function
  • HDF/high flux   :Not dialysed. Dose as in normal renal function
  • CAV/VVHD      :Not dialysed. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs
  • None known

    ADMINISTRATION

    Reconstition

    Route

    Oral

    Rate of Administration

    Comments

    OTHER INFORMATION

    Metabolites have minimal therapeutic activity.



    See how to identify renal failure stages according to GFR calculation

    See how to diagnose irreversible renal disease

    Home

  • other drugs